托珠单抗治疗儿童热性感染相关性癫痫综合征2例并文献复习

doi:10.12372/jcp.2025.24e0426

Abstract

Abstract:

Objective To report the use of tocilizumab in 2 cases of children with febrile infection-ralated epilepsy syndrome (FIRES), and provide a reference for its therapeutic application. Methods A retrospective analysis was conducted on the clinical manifestations, diagnostic and treatment processes, and therapeutic responses to tocilizumab in two FIRES patients admitted to the pediatric intensive care unit of our hospital in 2023, and the relevant literatures were reviewed. Results Neither patient responded to multiple antiepileptic drugs, anesthetics, ketogenic diet therapy, or first-line immunotherapy (high-dose methylprednisolone and high-dose intravenous immunoglobulin). Following second-line immunotherapy with tocilizumab, epileptic seizures were effectively controlled without adverse reactions. After 4-6 months of follow-up, one patient experienced recurrence of epileptic seizures. Conclusions Tocilizumab demonstrates efficacy as a second-line immunotherapy for FIRES, with good tolerability, and represents a promising treatment option.

Key words: febrile infection-ralated epilepsy syndrome, tocilizumab, cytokine, child

CLC Number:

LI Fan, HUANG Xianjie, FAN Yazhen, ZHAO Jianchuang, CUI Chenhang, GUO Qiliang, QIAO Junying. Tocilizumab treatment for febrile infection-related epilepsy syndrome in children: 2 cases report and literature review[J].Journal of Clinical Pediatrics, 2025, 43(7): 532-538.

Figures/Tables 5

Figure 1

Figure 2

Figure 3

Figure 4

Table 1

Literature review of tocilizumab treated patients with FIRES"

病例	ASMs	麻醉剂	一线/二线免疫治疗	使用TCZ 距起病天数/d	TCZ剂量	TCZ后 IL-6水平 /pg·mL^-1	治疗效果	随访
1^[14]	VPA、LEV、LCS、PHT、PB	咪达唑仑、氯胺酮	PE/TCZ	21	4 mg·kg·次^-1，每周1次，共2次	血2.9	第二次后13 d，发作明显减少；语言运动恢复正常	急性期内癫痫发作，每月1~2次；3个月后发作更频繁，复查TL-6正常
2^[14]	LCS、LEV、PHT、CLB、TPM、VPA	咪达唑仑	IVMP，IVIG/TCZ	30	4 mg·kg·次^-1，每10天1次，共2次	血2.4	首剂后2~3天，发作明显减少，2~5次/天；语言、意识水平、运动正常	—
3^[17]	PHT、PER、LEV、VPA、LCS、CLB、PB	咪达唑仑、硫喷妥钠	IVMP，IVIG/TCZ	NA	4 mg·kg·次^-1，共2次，间隔时间不详	—	首剂后72小时，脑电和临床发作均停止，出院后应用4种ASMs	随访4月，癫痫未发作；mRS评分3分，在短期记忆、学习、执行功能方面轻度缺陷
4^[18]	LEV、PHT、PB、VPA、LCS、TPM、大麻二酚、劳拉西泮	咪达唑仑、氯胺酮、戊巴比妥	IVMP，IVIG/阿那白滞素、TCZ	20	12 mg·kg·次^-1，每2周1次，共4次	—	首剂后3天，发作减少，出院后应用5种ASMs	随访1年，每天发作0~1次；右侧颞叶内侧硬化；行为失调，注意力不集中
5^[19]	PB、VPA、TPM、LEV、PHT	咪达唑仑、戊巴比妥	IVMP，IVIG/TCZ、TAC、IT-DEX	36	8 mg·kg·次^-1，每周1次，共2次	血4.6，脑脊液1	发作暂时受抑制后复发，给予IT-DEX、再次IVMP，加TAC后好转	—
6^[7]	PB、VPA、LEV、TPM、OXC、LCS、CZP、PER、ZNS	异丙酚、咪达唑仑	IVMP，IVIG/TCZ	36	4 mg·kg·次^-1，每周1次，共2次	血正常	首剂应用后3天，发作减少50%以上，第二剂后10天，发作得到控制	3个月后再次发作，每月2~3次，随访10个月，mRS评分1分，智商76
7^[20]	LEV、VPA、TPM、PER、PB、GBP、CLB、VGB、RUF	咪达唑仑、异丙酚、硫喷妥钠、氯胺酮	IVMP，IVIG，PE/托法替尼、TCZ、阿那白滞素	51	前4次8 mg·kg·次^-1，每2周1次；后3次每月1次	下降，数值不详	首次应用后16天，显著临床和电反应，发作改善	最低意识状态，康复治疗
8^[21]	CZP、FPHT、LEV、PB、LCS	咪达唑仑、异丙酚、氯胺酮	IVMP，IVIG，PE/TCZ	17	4 mg·kg·次^-1，d17，d23	—	首剂后2天撤机，4天抽搐停止，10天脑电图背景活动正常，28天出院	1年后，每月局灶性发作，脑电图示左颞慢波。轻度注意力缺陷，神经心理评估正常

Table 1

References 21

[1]	Payne ET, Koh S, Wirrell EC. Extinguishing febrile infection-related epilepsy syndrome: pipe dream or reality?[J]. Semin Neurol, 2020, 40(2): 263-272.
[2]	Van Baalen A, Vezzani A, Häusler M, et al. Febrile infection-related epilepsy syndrome: clinical review and hypotheses of epileptogenesis[J]. Neuropediatrics, 2017, 48(1): 5-18. doi: 10.1055/s-0036-1597271 pmid: 27919115
[3]	Wickström R, Taraschenko O, Dilena R, et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including febrile infection‐related epilepsy syndrome (FIRES): summary and clinical tools[J]. Epilepsia, 2022, 63(11):2827-2839.
[4]	Wickstrom R, Taraschenko O, Dilena R, et al. International consensus recommendations for management of New Onset Refractory Status Epilepticus (NORSE) incl. Febrile Infection-Related Epilepsy Syndrome (FIRES): statements and supporting evidence[J]. Epilepsia, 2022, 63(11): 2840-2864.
[5]	Lee GH, Kim J, Kim HW, et al. Clinical significance of Epstein-Barr virus in the cerebrospinal fluid of immunocompetent patients[J]. Clin Neurol Neurosurg, 2021, 202: 106507.
[6]	中华医学会神经病学分会感染性疾病与脑脊液细胞学学组. 中枢神经系统感染性疾病的脑脊液宏基因组学第二代测序应用专家共识[J]. 中华神经科杂志, 2021, 54(12): 1234-1240.
	Chinese Society of Infectious Diseases and Cerebrospinal Fluid Cytology. Expert consensus on clinical application of metagenomic nextgeneration sequencing of cerebrospinal fluid in the diagnosis of infectious diseases of the central nervous system[J]. Zhonghua Shenjingke Zazhi, 2021, 54(12): 1234-1240.
[7]	王营, 马燕丽, 王媛, 等. 托珠单抗成功治疗儿童发热感染相关癫痫综合征1例及文献复习[J]. 中华神经科杂志, 2022, 55(11): 1277-1285.
	Wang Y, Ma YL, Wang Y, et al. A case of febrile infectionrelated epilepsy syndrome in children successfully treated with tocilizumab and literature review[J]. Zhonghua Shenjingke Zazhi, 2022, 55(11): 1277-1285.
[8]	Hirsch LJ, Gaspard N, Van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions[J]. Epilepsia, 2018, 59(4): 739-744. doi: 10.1111/epi.14016 pmid: 29399791
[9]	Mantoan Ritter L, Nashef L. New-onset refractory status epilepticus (NORSE)[J]. Pract Neurol, 2021: practneurol-2020-002534.
[10]	Van Baalen A. Febrile infection-related epilepsy syndrome in childhood: A clinical review and practical approach[J]. Seizure, 2023, 111: 215-222. doi: 10.1016/j.seizure.2023.09.008 pmid: 37703593
[11]	Hanin A, Cespedes J, Dorgham K, et al. Cytokines in new-onset refractory status epilepticus predict outcomes[J]. Ann Neurol, 2023, 94(1): 75-90. doi: 10.1002/ana.26627 pmid: 36871188
[12]	Sakuma H, Horino A, Kuki I. Neurocritical care and target immunotherapy for febrile infection-related epilepsy syndrome[J]. Biomed J, 2020, 43(3): 205-210. doi: S2319-4170(20)30038-X pmid: 32330681
[13]	Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra)[J]. Hum Vaccin Immunother, 2017, 13(9): 1972-1988.
[14]	Cantarín-Extremera V, Jiménez-Legido M, Duat-Rodríguez A, et al. Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients[J]. J Neuroimmunol, 2020, 340: 577142.
[15]	Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease[J]. Blood, 2008, 112(10): 3959-3964. doi: 10.1182/blood-2008-05-155846 pmid: 18784373
[16]	Aledo-Serrano A, Hariramani R, Gonzalez-Martinez A, et al. Anakinra and tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome (FIRES): effectiveness and safety from a case-series[J]. Seizure, 2022, 100: 51-55. doi: 10.1016/j.seizure.2022.06.012 pmid: 35759951
[17]	Chee YC, Lim CH, Abdul Halim S, et al. Extinguishing FIRES using tocilizumab[J]. Neurology and Clinical Neuroscience, 2020, 8(4): 192-195.
[18]	Stredny CM, Case S, Sansevere AJ, et al. Interleukin-6 blockade with tocilizumab in anakinra-refractory febrile infection-related epilepsy syndrome (FIRES)[J]. Child Neurol Open, 2020, 7: 2329048x20979253.
[19]	Kurimoto T, Matsuoka T, Ami Y, et al. Anti-inflammatory and immune-mediated therapy for a case of febrile infection-related epilepsy syndrome with rapid recurrence[J]. Clin Case Rep, 2022, 10(6): e5952.
[20]	Goh Y, Tay SH, Yeo LLL, et al. Bridging the gap: tailoring an approach to treatment in febrile infection-related epilepsy syndrome[J]. Neurology, 2023, 100(24): 1151-1155. doi: 10.1212/WNL.0000000000207068 pmid: 36797068
[21]	Girardin ML, Flamand T, Roignot O, et al. Treatment of new onset refractory status epilepticus/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult[J]. Epilepsia, 2023, 64(6): e87-e92.

Tocilizumab treatment for febrile infection-related epilepsy syndrome in children: 2 cases report and literature review

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 21

Related Articles 15

Metrics

Comments

Recommended 0

[1]	Chinese Cooperative Group for the Management of Pediatric Enuresis Affiliated to Pediatric Nephrology Committee of Chinese Medical Doctor Association. Chinese expert consensus on management of nocturnal enuresis in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 483-499.
[2]	WANG Yingshuo, CHEN Zhimin. Leveraging digital intelligence to enhance the diagnosis, treatment, and management of pediatric bronchial asthma [J]. Journal of Clinical Pediatrics, 2025, 43(7): 500-504.
[3]	ZHAO Linchao, WANG Yingjie, JING Zhaohe, MAI Yumiao, SUN Pan, QIU Simin, NIU Hongyun, CHEN Zhiwei, DONG Pengpeng, LIU Jian. Analysis of the efficacy and prognosis of hematopoietic stem cell transplantation for inherited bone marrow failure syndrome in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 505-510.
[4]	ZHANG Zhiqi, XIONG Ruolan, LI Bohan, JI Qi, WANG Qingwei, LU Jun, LI Jie, XIAO Peifang, HU Shaoyan. Construction of risk prediction model for primary graft failure after umbilical cord blood transplantation in pediatric leukemia [J]. Journal of Clinical Pediatrics, 2025, 43(7): 511-518.
[5]	JIANG Wenwen, LI Sitong, XU Yongsheng. Analysis on risk factors associated with false-negative results of interferon-gamma release assay in children with pulmonary tuberculosis [J]. Journal of Clinical Pediatrics, 2025, 43(7): 519-524.
[6]	DUAN Haolin, ZHANG Ciliu, XIONG Juan, PANG Nan, YIN Fei, PENG Jing. Clinical efficacy analysis of disease-modifying therapies for spinal muscular atrophy with SMN1 gene compound heterozygous variants [J]. Journal of Clinical Pediatrics, 2025, 43(7): 543-548.
[7]	HE Shuang, XU Xin, ZHOU Xue, LIU Qian, ZHANG Lei, TIAN Jie, LYU Tiewei. Leadless cardiac pacemaker implantation via the internal jugular vein: clinical practice and reflection of a 15kg child with third-degree atrioventricular block after congenital heart surgery [J]. Journal of Clinical Pediatrics, 2025, 43(7): 549-553.
[8]	LI Fen. Promoting the research and application of leadless cardiac pacemakers in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 554-555.
[9]	LYU Mingjun, LUO Wen, YANG Jinxiang, LIANG Jianying, YAO Zhirong. Progress in pathogenesis and treatment of pediatric generalized pustular psoriasis [J]. Journal of Clinical Pediatrics, 2025, 43(7): 556-562.
[10]	ZHANG Hongwen. Application and consideration of eculizumab in the treatment of childhood systemic lupus erythematosus [J]. Journal of Clinical Pediatrics, 2025, 43(6): 403-407.
[11]	LI Qiuyu, LIU Fei, ZHAO Manli, GU Weizhong, FENG Chunyue, FU Haidong. Clinicopathological analysis of 3496 pediatric patients with renal disease: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2025, 43(6): 411-417.
[12]	WANG Ruixue, WANG Runjie, LI Xiaolu, ZHANG Ting, XIAO Yongmei. Analysis of clinical characteristics, endoscopic and pathological manifestations of children with positive lactulose hydrogen-methane breath test [J]. Journal of Clinical Pediatrics, 2025, 43(6): 418-425.
[13]	YUE Yang, ZHANG Zhihua, LI Mei, LIU Zhifeng, GUO Hongmei. Predictors of efficacy of infliximab induction therapy in children with Crohn's disease [J]. Journal of Clinical Pediatrics, 2025, 43(6): 426-431.
[14]	XIE Lilin, XU Jinping, YAO Yonghua. Pediatric arterial ischemic stroke: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2025, 43(6): 432-437.
[15]	DU Tingting, YAO Hui, CHEN Xiaohong, YANG Luhong, FENG Lifang, CHEN Xiaoqian, HU Man, LI Yakun. A study examining the association between hypopituitarism and metabolic-associated fatty liver disease following surgery for tumors in the sellar region among children [J]. Journal of Clinical Pediatrics, 2025, 43(6): 438-444.